BFNH · BioForce Nanosciences Holdings, Inc.

Escalating Losses and the Liability Settlement Impact

Zero Revenue and the Absence of Commercial Traction

For the second consecutive fiscal year, BioForce reported zero revenue and zero unit sales of its 'BioForce Eclipse' nutritional supplement product. This complete lack of commercial traction is the foundational challenge underlying all other financial metrics. The income statement shows no sales, cost of goods sold, or gross profit. Management's business description outlines ambitions in the vitamin and supplement industry, but the financial results reflect a pre-revenue development stage company that has not yet translated its business plan into market sales. This ongoing revenue drought directly fuels the operating losses and cash burn.

Critical Liquidity Crisis and Going Concern Warning

The company's liquidity position remains critically constrained. Net cash used in operating activities was -$65,150 for the year, reflecting persistent cash burn as operations are funded without revenue. Management has explicitly stated that the company's significant operating losses raise substantial doubt about its ability to continue as a going concern. They further warn that if sufficient capital is not obtained, the company will not be able to continue operations, execute its business plan, or respond to competitive pressures. This highlights an existential dependence on securing immediate external financing.

Operational Context and Cost Structure

Within this challenging environment, management noted a slight decrease in General and Administrative expenses, attributing it primarily to lower professional service fees. However, this minor cost reduction was insufficient to offset the broader financial pressures. The company continues to operate without sufficient revenues to cover its operating expenses, a fundamental issue that management acknowledges. The financial structure remains heavily reliant on external funding to sustain even basic administrative functions.

Strategic Outlook and Existential Dependence on Financing

The company's future is entirely contingent on its ability to raise capital. Management's outlook is clear: without obtaining needed funds on acceptable terms, BioForce will not be able to continue operations, develop services, or pursue opportunities. This creates a binary outcome for investors—either the company secures financing and attempts to advance its business plan, or it faces potential cessation of operations. The financial statements reflect this precarious position, with losses mounting and cash resources being depleted to fund ongoing activities in the absence of commercial success.